Summary & Overview
HCPCS J3489: Injection, Zoledronic Acid, 1 mg
HCPCS Level II code J3489 designates a 1 mg injection of zoledronic acid, a parenteral bisphosphonate used in clinical practice for conditions requiring anti-resorptive therapy. Nationally, this code matters for accurate drug billing, inventory tracking, and outpatient infusion reimbursement because zoledronic acid is commonly administered in infusion suites and clinic settings.
Key payers included in this overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what J3489 represents clinically and administratively, plus an overview of typical sites of service. The publication outlines benchmark considerations for coverage and payment, common modifier usage for billing scenarios, and clinical context for use of zoledronic acid in outpatient infusion settings. Where payer-specific policies exist, the analysis summarizes standard coverage themes and prior authorization patterns.
This summary equips clinicians, billing staff, and policy analysts with the core coding and service-context information needed to identify when J3489 applies, how it is presented on service lines, and what elements to review in payer policies and claim adjudication workflows.
Billing Code Overview
HCPCS Level II code J3489 represents an injection of zoledronic acid, 1 mg. This entry describes a single-dose parenteral medication delivery used in clinical settings that administer intravenous or intramuscular therapies. The service type is injectable medication administration, and the typical site of service is outpatient infusion or clinic-based administration such as oncology clinics, infusion centers, or hospital outpatient departments.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a postmenopausal woman or an adult with malignancy-related bone disease who presents to an outpatient infusion center or hospital outpatient department for administration of intravenous zoledronic acid (J3489, per 1 mg unit). The patient has a documented diagnosis such as osteoporosis, Paget disease of bone, or bone metastases and has an order for a single-dose intravenous infusion of zoledronic acid. The clinical workflow includes pre-infusion assessment (vital signs, review of renal function and serum calcium), verification of informed consent and medication order, preparation of the appropriate dose by pharmacy, administration via peripheral or central IV access by an infusion nurse, monitoring for acute infusion reactions during and for at least 15–30 minutes after infusion, documentation of dose and lot number, and billing using the HCPCS Level II code J3489 with applicable modifiers based on payer and clinical circumstances. Typical site of service is an outpatient infusion center, hospital outpatient department, or oncology clinic infusion suite.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the day of a procedure | Use when the clinician documents a distinct E/M encounter on the same day as (e.g., urgent visit with separate decision-making). |